PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CMA launches formal investigation into COVID-19 PCR test firm

The UK’s Competitions and Markets Authority (CMA) has launched a formal investigation into private firm Expert Medicals, following complaints relating to its provision of COVID-19 PCR tests in the UK.

In August, UK Health and Social Care Secretary Sajid Javid asked the CMA to conduct a rapid, high-level review of the market for PCR travel tests.

In an open letter to Andrea Coscelli, chief executive of the CMA, Javid acknowledged the cost of PCR testing can be prohibitively expensive – in particular for families who want to travel together.

The CMA has launched an investigation into Expert Medicals following complaints accusing the company of failing to provide tests and results in a timely manner or at all, as well as failing to respond to customer complaints and refusing to issue refunds.

According to the CMA, Expert Medicals has been the subject of a ‘high number of complaints’ in the UK – to the point where the company no longer appears on the list of PCR test providers who self-declare that they meet the government’s minimum standards for COVID-19 testing.

In addition to the formal investigation launch, the CMA has written to a further 19 test providers with a warning to improve their pricing information or ‘risk action in the future’.

“Millions of people have to buy PCR tests in order to travel. If we find that firms have been misleading customers and failing to provide the service that people have paid for, we stand ready to take action,” said Coscelli.

“Our actions today are the next steps in our work to ensure the PCR testing market works for consumers and we are preparing to take further action in this sector,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026